‘Pluck those di­a­monds’: Bay­er’s Vi­vid­ion eyes up to nine on­col­o­gy tar­gets from Duke spin­out

Af­ter snap­ping up Vi­vid­ion be­fore it could jump on­to Nas­daq last Au­gust, Bay­er’s pre­clin­i­cal ‘arms-length’ sub­sidiary is bet­ting on a rel­a­tive­ly un­known North Car­oli­na up­start in a five-year pact.

The ini­tial fo­cus con­cerns four tar­gets, but the deal with Durham-based Tavros Ther­a­peu­tics could bal­loon by an­oth­er five tar­gets, which would more than dou­ble the terms from $430.5 mil­lion in mile­stones to a whop­ping $912 mil­lion. Ei­ther way, the 14-em­ploy­ee Tavros gets $17.5 mil­lion up­front.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER